Rate My Professor Paul Glue

Professor Paul Glue is the Hazel Buckland Chair of Psychiatry in the Department of Psychological Medicine at the University of Otago's Dunedin School of Medicine, part of the Faculty of Medicine. He graduated from Otago Medical School in 1980 with an MB ChB and holds an MD. Glue completed his psychiatry training in Auckland, New Zealand, and Oxford, United Kingdom, obtaining Membership of the Royal College of Psychiatrists (MRCPsych) in 1986 and Fellowship (FRCPsych) in 2010. Prior to his current roles, he spent 18 years in the pharmaceutical industry conducting translational clinical pharmacology research. Since 2009, he has served as a consultant psychiatrist in adult general psychiatry for the Southern District Health Board. At the University of Otago, he is recognized as Professor of Psychiatry and contributes to academic staff, supervising PhD students and participating in clinical trials.

Glue's research specializations center on psychopharmacology, with a focus on ketamine and psychedelic-assisted psychotherapy for treatment-resistant depression, anxiety disorders, and mood disorders. He has authored over 480 papers and abstracts, holds 13 patents, and has received several international research awards and prizes. His influential publications include 'Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial' (Nature Medicine, 2024), 'Ketamine for treatment-resistant major depressive disorder' (PMC, 2024), 'Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis' (International Journal of Neuropsychopharmacology, 2016, 289 citations), 'Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression' (Acta Psychiatrica Scandinavica, 2016, 271 citations), and 'Model-based drug development' (Clinical Pharmacology & Therapeutics, 2007, 570 citations). Earlier works encompass hepatitis treatments like 'Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data' (Clinical Pharmacology & Therapeutics, 2000, 733 citations). Glue's contributions have advanced novel pharmacological interventions, evidenced by his leadership in ketamine studies demonstrating promise for depression treatment and his expertise in pharmaceutical development.